OR WAIT null SECS
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
Given the criticality of fill/finish processes, it is clear that automation is the next technological step.
June 21, 2023
India’s Enzene Biosciences is investing $50 Million into a new biopharma manufacturing plant in Hopewell, NJ.
June 20, 2023
The new facility also provides a plan for scalable product production processes that can potentially be replicated by Vaxxas domestically and globally.
June 15, 2023
Mendus and NorthX Biologics will work to develop and commercialize Mendus’ lead asset, vididencel, an allogeneic dendritic cell vaccine.
Charles River’s off-the-shelf lentiviral vector packaging plasmids are intended for use with cell and gene therapies.
June 14, 2023
The new excipients manufacturing facility is expected to be completed in 2025.
June 08, 2023
The collaboration between Samsung Biologics and Pfizer will focus on long-term biosimilars manufacturing.
June 07, 2023
Webinar Date/Time: Tuesday, June 27th, 2023 at 8am EDT | 1pm BST | 2pm CEST | 5am PDT Wednesday, June 28th, 2023 at 8am EDT | 1pm BST | 2pm CEST | 5am PDT Thursday, June 29th, 2023 at 8am EDT | 1pm BST | 2pm CEST | 5am PDT
June 06, 2023
invoX Pharma has made a second tranche of investment in pHion Therapeutics to support further development of next-generation mRNA vaccines.
June 02, 2023
Manufacturers must figure out how flexible they need to be to meet the numerous new requirements of the changing therapeutic and regulatory landscapes.
Makers of specialty biologics, gene therapies, and other personalized medicines are working to identify and reduce potential supply chain risks both upstream and downstream.